Stock Ratings / Health Care / CTOR / insiders

MREO (42) ATNM (42) SER (43) ELTX (31) ⌘ Pro Terminal →

Citius Oncology Inc. (CTOR) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Are CTOR insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies CTOR leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

$0.53 -8.20% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.52

Citius Oncology Inc. (CTOR) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $49.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.52 (-1.67%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CTOR)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (39/100 Composite)

🔍 WHY CTOR SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (28% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.84-8.3% Next Q

Q2 (-2Q)

Grade D$0.77-24.7% Next Q

Q3 (-1Q)

Grade D$0.58-8.6% Next Q

Current

Grade D-$0.53-7.6% Hist 90D α

Trajectory: D (47) → D- (39)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CTOR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CTOR currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.84) and Max Pain ($0.56) forces dealer call-delta covering toward $1.92.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CTOR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CTOR Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 39%NO 61%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

CTOR Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (CTOR)

No recent open-market Form 4 cluster sales or emergency dumps flagged on CTOR. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CTOR)

✓Walkthrough of CTOR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CTOR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -39.77%▼ SUPPORT BREAKDOWN

2026-10-30O $0.53H $0.56L $0.50C $0.53VOL 291.3K

RES: $1.33SUP: $0.66SMA50: $0.84SMA200: $0.83

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CTOR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CTOR Butterfly Map → + Track CTOR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CTOR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CTOR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CTOR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CTOR)

Health Care Rank #679 of 1016 ⚔️ MREO vs CTOR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CTOR vs. MREO, ATNM, SER, ELTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Citius Oncology Inc. (CTOR) ranks #679 by composite RQD confidence (39/100, grade D-) and #753 by equity capitalization ($49.2M). Within this direct 5-issuer industry benchmark cohort, CTOR leads on earnings valuation at N/A trailing P/E, while CTOR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SER currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with CTOR at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CTOR ACTIVE Citius Oncology Inc.	D-	39/100	—	—	-35.0%	-8.20%	$49.2M	Benchmark Subject
MREO Mereo BioPharma Group plc	D-	42/100	—	—	-35.0%	+1.62%	$48.2M	/mreo-vs-ctor →
ATNM Actinium Pharmaceuticals Inc. (Delaware)	D-	42/100	—	—	-35.0%	+10.87%	$48.1M	/atnm-vs-ctor →
SER Serina Therapeutics Inc.	D-	43/100	—	—	-35.0%	+15.24%	$48.0M	/ser-vs-ctor →
ELTX Elicio Therapeutics Inc.	E	31/100	—	—	-35.0%	-5.40%	$47.4M	/eltx-vs-ctor →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001851484

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Citius Oncology Inc. (CTOR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$24.8M, operating cash flow of -$5.5M, and free cash flow of -$5.5M (-4446.6% YoY). On the balance sheet, CTOR closed FY2025 with $110.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-09-30	$0	-$24.8M	-$5.5M	-$5.5M	$110.0M	—
FY2024 (FY)	2024-09-30	$0	-$21.1M	$126.4K	$126.4K	$90.5M	—
FY2023 (FY)	2023-12-31	$0	$2.4M	-$601.3K	-$601.3K	—	—

3. CTOR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CTOR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Citius Oncology Inc. (NASDAQ: CTOR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $0.53 (-8.20% 1D, market cap $49.2M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CTOR ranks #679 in composite RQD confidence.

How does CTOR compare to MREO and ATNM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CTOR carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MREO (Mereo BioPharma Group plc) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $48.2M) and ATNM (Actinium Pharmaceuticals Inc. (Delaware)) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $48.1M). Among the 5-stock peer group, CTOR leads on earnings multiple (N/A) while CTOR leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CTOR?

Per CTOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001851484), Citius Oncology Inc. generated $0 in revenue, -$24.8M in net income, and -$5.5M in free cash flow against $110.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CTOR trading relative to its 50-day, 200-day, and 52-week technical levels?

CTOR last traded at $0.53 (-8.20% on volume of 195,085 shares), positioning the stock -36.90% below its 50-day simple moving average ($0.84) and -36.14% below its 200-day simple moving average ($0.83). Across its 52-week range of $0.49 to $1.83, CTOR sits at the 3.0% percentile with a 14-day RSI of 29.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.60).

CTOR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are CTOR insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies CTOR leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: CTOR RQD Cockpit CTOR 12M Forecast CTOR Earnings & Move CTOR Dividends & DRIP CTOR Insiders & 13F CTOR Whale Options CTOR Profit Sankey CTOR News & Why